Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 1
2006 1
2007 1
2010 9
2011 2
2012 3
2013 5
2014 7
2015 16
2016 12
2017 16
2018 18
2019 11
2020 20
2021 12
2022 18
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean eligulstat OR Genz-112638 (149 results)?
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. Stirnemann J, et al. Int J Mol Sci. 2017 Feb 17;18(2):441. doi: 10.3390/ijms18020441. Int J Mol Sci. 2017. PMID: 28218669 Free PMC article. Review.
Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat)....
Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat)....
Eliglustat.
[No authors listed] [No authors listed] 2020 Apr 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Apr 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 32352701 Free Books & Documents. Review.
Because there is no published experience with eliglustat during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.[1]...
Because there is no published experience with eliglustat during breastfeeding, an alternate drug may be preferred, especially while n …
Gaucher Disease.
Hughes DA, Pastores GM. Hughes DA, et al. 2000 Jul 27 [updated 2023 Dec 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2000 Jul 27 [updated 2023 Dec 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301446 Free Books & Documents. Review.
MANAGEMENT: Targeted therapy: Options include enzyme replacement therapy (ERT) or substrate reduction therapy (SRT; e.g., miglustat, eliglustat). Hematopoietic stem cell transplantation may be an option in individuals with severe GD, primarily those with chronic neurologic …
MANAGEMENT: Targeted therapy: Options include enzyme replacement therapy (ERT) or substrate reduction therapy (SRT; e.g., miglustat, elig …
Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition.
Jain V, Harper SL, Versace AM, Fingerman D, Brown GS, Bhardwaj M, Crissey MAS, Goldman AR, Ruthel G, Liu Q, Zivkovic A, Stark H, Herlyn M, Gimotty PA, Speicher DW, Amaravadi RK. Jain V, et al. Cancer Discov. 2023 Feb 6;13(2):454-473. doi: 10.1158/2159-8290.CD-22-0535. Cancer Discov. 2023. PMID: 36331284 Free PMC article.
Melanoma patients with high UGCG expression had significantly shorter disease-specific survival. The FDA-approved UGCG inhibitor eliglustat combined with LAI significantly inhibited tumor growth and improved survival in syngeneic tumors and a therapy-resistant patient-deri …
Melanoma patients with high UGCG expression had significantly shorter disease-specific survival. The FDA-approved UGCG inhibitor eliglust …
Eliglustat Therapy and CYP2D6 Genotype.
Kane M, Dean L. Kane M, et al. 2020 Dec 22. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2020 Dec 22. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 33351401 Free Books & Documents. Review.
Eliglustat (brand name CERDELGA) is a glucosylceramide synthase inhibitor used in the treatment of Gaucher disease (GD). ...Eliglustat is broken down to inactive metabolites by CYP2D6 and, to a lesser extent, CYP3A (3). ...
Eliglustat (brand name CERDELGA) is a glucosylceramide synthase inhibitor used in the treatment of Gaucher disease (GD). ...Eliglu …
Eliglustat.
[No authors listed] [No authors listed] 2018 Mar 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Mar 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644156 Free Books & Documents. Review.
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease. Clinical experience with eliglustat is limited, but it not been linked to serum enzyme elevations during therapy or to instances of clinically appare …
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease. Clinical experie …
Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM, Charrow J, Lukina E, Mistry PK, Foster MC, Peterschmitt MJ. Cox TM, et al. Genet Med. 2023 Feb;25(2):100329. doi: 10.1016/j.gim.2022.10.011. Epub 2022 Dec 5. Genet Med. 2023. PMID: 36469032 Free article.
METHODS: Data from 4 completed phase 2 and 3 trials were evaluated in treatment-naive patients or patients switching to eliglustat from enzyme replacement therapy (ERT). RESULTS: Overall, 319 of 393 (81%) eliglustat-treated patients remained in their trials until co …
METHODS: Data from 4 completed phase 2 and 3 trials were evaluated in treatment-naive patients or patients switching to eliglustat fr …
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
Leng H, Zhang H, Li L, Zhang S, Wang Y, Chavda SJ, Galas-Filipowicz D, Lou H, Ersek A, Morris EV, Sezgin E, Lee YH, Li Y, Lechuga-Vieco AV, Tian M, Mi JQ, Yong K, Zhong Q, Edwards CM, Simon AK, Horwood NJ. Leng H, et al. Nat Commun. 2022 Dec 22;13(1):7868. doi: 10.1038/s41467-022-35358-3. Nat Commun. 2022. PMID: 36550101 Free PMC article.
In combination with zoledronic acid, a bisphosphonate that treats myeloma bone disease, eliglustat provided further protection from bone loss. Autophagic degradation of TRAF3, a key step for osteoclast differentiation, was inhibited by eliglustat as evidenced by TRA …
In combination with zoledronic acid, a bisphosphonate that treats myeloma bone disease, eliglustat provided further protection from b …
Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ. Scott LJ. Drugs. 2015 Sep;75(14):1669-78. doi: 10.1007/s40265-015-0468-9. Drugs. 2015. PMID: 26384672 Review.
In the 9-month phase 3 ENGAGE trial, eliglustat significantly improved haematological endpoints and reduced organomegaly compared with placebo in treatment-naive adults with GD1, with the bone marrow burden score (a marker of Gaucher cell infiltration) and GD1 biomarkers a …
In the 9-month phase 3 ENGAGE trial, eliglustat significantly improved haematological endpoints and reduced organomegaly compared wit …
Pharmacoeconomic Review Report: Eliglustat (Cerdelga): (Sanofi Genzyme): Indication: Gaucher Disease Type 1.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Aug. PMID: 30516941 Free Books & Documents. Review.
The same transition probabilities for eliglustat and the ERTs for health states were adopted from the ENGAGE and ENCORE studies (short-term) and a retrospective cohort study (long-term). Data from manufacturer-commissioned reports and the published studies of eliglustat …
The same transition probabilities for eliglustat and the ERTs for health states were adopted from the ENGAGE and ENCORE studies (shor …
148 results